Bolt Biotherapeutics, Inc. (BOLT)

Over the past six months, BOLT's stock price has been impacted by several events. In October 2025, a workforce reduction and clinical trial delay were announced. The Q3 2025 earnings report was released on November 12, 2025, with an EPS of -$3.72. On March 12, 2026, the company reported its Q4 and full-year 2025 financial results, posting a Q4 loss of $3.84 per share. In February 2026, Bolt Biotherapeutics announced its participation in upcoming March conferences. The share price as of April 8, 2026, was $4.60, representing a decline of 28.13% from April 8, 2025, and a decrease of 10.2% from January 1, 2026, to April 11, 2026.

As a clinical-stage biopharmaceutical company, Bolt Biotherapeutics' products are still in development, and traditional demand seasonality does not apply. The demand for its research and development activities and clinical trials is driven by ongoing scientific and medical needs in oncology.

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer, operating in the Biotechnology and Pharmaceutical Preparations industry. The company leverages its Boltbody™ ISAC platform to harness the innate and adaptive immune systems for anti-tumor responses. Key pipeline products include BDC-4182 (Phase 1 for various cancers), BDC-3042 (completed Phase 1, seeking a partner), CEA ISAC (preclinical, on hold), and PD-L1 ISAC (preclinical, on hold). Bolt Biotherapeutics has strategic collaborations with Genmab and Toray Industries, Inc.

Bolt Biotherapeutics, Inc. is headquartered in Redwood City, California, United States. Clinical trials for BDC-4182 commenced in Australia and are planned to expand to other countries.

Bolt Biotherapeutics' reputation has been affected by several events in the past year. A class-action lawsuit was filed in July 2024 alleging misleading investors regarding BDC-1001. The discontinuation of BDC-1001 in May 2024 led to a workforce reduction and stock price drop. Further workforce reductions occurred in August 2024 and October 2025. The delay in the readout of initial data for BDC-4182 could also be perceived negatively.

As of April 8, 2026, Bolt Biotherapeutics, Inc. has 23 institutional owners and shareholders holding a total of 602,538 shares, representing 86.70% of the stock. Major institutional owners include Sofinnova Investments, Inc., Pivotal bioVenture Partners Investment Advisor LLC, Vivo Capital, LLC, Nan Fung Group Holdings Ltd, Renaissance Technologies Llc, T3 Companies, LLC, Board of Trustees of The Leland Stanford Junior University, Pfizer Inc, Geode Capital Management, Llc, and BlackRock, Inc.